These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 27308516)

  • 1. p85α neomorphic mutants: splitting away from the canonical path.
    Cheung LW; Mills GB
    Mol Cell Oncol; 2015; 2(4):e983388. PubMed ID: 27308516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.
    Cheung LW; Yu S; Zhang D; Li J; Ng PK; Panupinthu N; Mitra S; Ju Z; Yu Q; Liang H; Hawke DH; Lu Y; Broaddus RR; Mills GB
    Cancer Cell; 2014 Oct; 26(4):479-94. PubMed ID: 25284480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The double life of p85.
    Costa C; Engelman JA
    Cancer Cell; 2014 Oct; 26(4):445-7. PubMed ID: 25314071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment.
    Cheung LW; Mills GB
    Pharmacogenomics; 2016 Feb; 17(3):297-307. PubMed ID: 26807692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.
    Thorpe LM; Spangle JM; Ohlson CE; Cheng H; Roberts TM; Cantley LC; Zhao JJ
    Proc Natl Acad Sci U S A; 2017 Jul; 114(27):7095-7100. PubMed ID: 28630349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The p85 regulatory subunit of PI3K mediates TSH-cAMP-PKA growth and survival signals.
    De Gregorio G; Coppa A; Cosentino C; Ucci S; Messina S; Nicolussi A; D'Inzeo S; Di Pardo A; Avvedimento EV; Porcellini A
    Oncogene; 2007 Mar; 26(14):2039-47. PubMed ID: 17043656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p85 regulatory subunit of PI3K mediates cAMP-PKA and estrogens biological effects on growth and survival.
    Cosentino C; Di Domenico M; Porcellini A; Cuozzo C; De Gregorio G; Santillo MR; Agnese S; Di Stasio R; Feliciello A; Migliaccio A; Avvedimento EV
    Oncogene; 2007 Mar; 26(14):2095-103. PubMed ID: 17016431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer.
    Yan LX; Liu YH; Xiang JW; Wu QN; Xu LB; Luo XL; Zhu XL; Liu C; Xu FP; Luo DL; Mei P; Xu J; Zhang KP; Chen J
    Int J Oncol; 2016 Feb; 48(2):471-84. PubMed ID: 26676464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Domain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85α and p85β.
    Ito Y; Vogt PK; Hart JR
    Oncotarget; 2017 Aug; 8(34):55863-55876. PubMed ID: 28915558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
    Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into the pathological mechanisms of p85α mutations using a yeast-based phosphatidylinositol 3-kinase model.
    Oliver MD; Fernández-Acero T; Luna S; Rodríguez-Escudero I; Molina M; Pulido R; Cid VJ
    Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28143957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K.
    Lucas CL; Zhang Y; Venida A; Wang Y; Hughes J; McElwee J; Butrick M; Matthews H; Price S; Biancalana M; Wang X; Richards M; Pozos T; Barlan I; Ozen A; Rao VK; Su HC; Lenardo MJ
    J Exp Med; 2014 Dec; 211(13):2537-47. PubMed ID: 25488983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of p85α Alterations in Cancer.
    Marshall JDS; Whitecross DE; Mellor P; Anderson DH
    Biomolecules; 2019 Jan; 9(1):. PubMed ID: 30650664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
    Echeverria I; Liu Y; Gabelli SB; Amzel LM
    FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.
    Hofmann BT; Jücker M
    Cell Signal; 2012 Oct; 24(10):1950-4. PubMed ID: 22735814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
    Ren SY; Xue F; Feng J; Skorski T
    Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin resistance and diabetes caused by genetic or diet-induced KBTBD2 deficiency in mice.
    Zhang Z; Turer E; Li X; Zhan X; Choi M; Tang M; Press A; Smith SR; Divoux A; Moresco EM; Beutler B
    Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6418-E6426. PubMed ID: 27708159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGF-β promotes PI3K-AKT signaling and prostate cancer cell migration through the TRAF6-mediated ubiquitylation of p85α.
    Hamidi A; Song J; Thakur N; Itoh S; Marcusson A; Bergh A; Heldin CH; Landström M
    Sci Signal; 2017 Jul; 10(486):. PubMed ID: 28676490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
    Yazdani R; Hamidi Z; Babaha F; Azizi G; Fekrvand S; Abolhassani H; Aghamohammadi A
    Endocr Metab Immune Disord Drug Targets; 2019; 19(7):941-958. PubMed ID: 30799802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
    Dornan GL; Burke JE
    Front Immunol; 2018; 9():575. PubMed ID: 29616047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.